Excellent publication of our partner CBG

Excellent publication of our partner CBG about how biomarkers shape the decision-making in personalized medicine

The PRIME-CKD consortium is proud to share with you our first publication by our partner CBG.

This study looks closely at how biomarkers have been used in patient selection for clinical precision medicine trials developing medicines that are approved for use in Europe. Biomarkers help scientists understand which person benefits most from the medicine, how studies are set up, and what the medicine can treat. They’re really important in the development of precise or personalized medicines. The findings in this study show how biomarkers help in creating these precise medicines and how they’re checked by regulators. This information can help in making better medicines in the future and encourage the use of precision medicine more widely.

You can find more information about this excellent article here: Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020 – Bakker – Clinical and Translational Science – Wiley Online Library